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Summary
Deletions on chromosome 22q11.21 disrupt pharyn-
geal and cardiac development and cause DiGeorge
and related human syndromes. CRKL (CRK-Like) lies
within 22q11.21, and Crkl2/2 mice have phenotypic
features of 22q11 deletion (del22q11) syndromes.
While human FGF8 does not localize to 22q11, defi-
ciency of Fgf8 also generates many features of
del22q11 syndrome in mice. Since Fgf8 signals via
receptor-type tyrosine kinases, and Crk family adaptor
proteins transduce intracellular signals downstream
of tyrosine kinases, we investigated whether Crkl
mediates Fgf8 signaling. In addition to discovering
genetic interactions between Crkl and Fgf8 during
morphogenesis of structures affected in del22q11 syn-
drome, we found that Fgf8 induces tyrosine phosphor-
ylation of FgfRs 1 and 2 and their binding to Crkl. Crkl
is required for normal cellular responses to Fgf8, in-
cluding survival and migration, Erk activation, and
target gene expression. These findings provide mech-
anistic insight into disrupted intercellular interactions
in the pathogenesis ofmalformations seen indel22q11
syndrome.
Introduction
Patients with DiGeorge, velocardiofacial, and CATCH-
22 syndromes suffer serious morbidity and mortality.
These ‘‘del22q11’’ syndromes include characteristic
malformations of the heart, outflow tract, and vascula-
ture, in addition to craniofacial defects and immune dys-
function due to abnormal thymic development. Although
a number of loci within del22q11 contribute to these
phenotypes, the functions of del22q11 genes in specific
molecular pathways mediating intercellular interactions
during cardiovascular and pharyngeal development
have yet to be determined (Lindsay, 2001; Scambler,
2000; Schinke and Izumo, 2001; Yamagishi and Srivas-
tava, 2003).
*Correspondence:anne.moon@genetics.utah.edu(A.M.M.); aimamoto@
uchicago.edu (A.I.)CRKL (CRK-Like) is located within the typically de-
leted region in patients with del22q11, and disruption
of its mouse ortholog, Crkl, causes cardiovascular, cra-
niofacial, and glandular features of del22q11 syndrome
(Guris et al., 2001). CRKL and related family members
encode adaptor proteins that play important roles dur-
ing intercellular signaling; they function in recruitment
and activation of signaling complexes at focal adhe-
sions and transduce intracellular signals downstream of
several classes of RTKs (Feller, 2001; Klint and Claes-
son-Welsh, 1999; Li et al., 2003).
Fgf8 encodes a secreted signaling protein required in
multiple expression domains to support normal cardio-
vascular development (Macatee et al., 2003; E. Park
and A.M.M., submitted). FGF8 is not located on human
22q11; however, Fgf8 deficiency during mouse embryo-
genesis produces a complex perinatal-lethal phenotype
that phenocopies human del22q11 syndrome (Abu-Issa
et al., 2002; Frank et al., 2002). Although it is not yet
known which Fgf receptors (FgfRs) specifically trans-
duce Fgf8 signals in vivo during cardiovascular and pha-
ryngeal development, shared gastrulation, limb, cranio-
facial, and vascular defects caused by mutations in
Fgf8, FgfR1, and FgfR2 in mice suggest important roles
for FgfRs 1 and 2 in these processes (Arman et al., 1998;
Celli et al., 1998; Deng et al., 1994, 1997; Rossant et al.,
1997; Sun et al., 1999; Trokovic et al., 2003; Xu et al.,
1998; L. Francis and A.M.M., unpublished data).
Formation of the Fgf ligand/FgfR complex causes
receptor autophosphorylation and triggers multiple in-
tracellular signaling cascades. Activated FgfRs bind
Src-homology2 (SH2) signaling proteins such as PLCg
and Shp-2 (Bottcher and Niehrs, 2005). A functional
link between Fgf signaling and Crk activity during
embryogenesis was suggested by the observation that
transduction of FgfR1-mediated intracellular signals in
endothelial cells depends on ligand-induced tyrosine
phosphorylation of FgfR1 on a residue bound by Crk
(Larsson et al., 1999).
These lines of evidence led us to hypothesize that
FGF8 and the adaptor protein CRKL function in a com-
mon molecular pathway that, when disrupted by hap-
loinsufficiency ofCRKL, contributes to the pathogenesis
of human del22q11 syndrome. We tested this hypothe-
sis by investigating the role of Crkl in Fgf8/FgfR signal
transduction required for normal pharyngeal arch and
cardiovascular development in genetically engineered
mice and embryonic cells derived therefrom.
Results
Fgf8 and Crkl Genetically Interact during
Mouse Morphogenesis
We used an Fgf8;Crkl allelic series in genetically engi-
neered mice to determine if Crkl and Fgf8 cooperatively
affect embryonic survival and morphogenesis of Fgf8-
sensitive structures including the cardiovascular sys-
tem, pharyngeal glands, and the craniofacial and appen-
dicular skeleton.
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72Figure 1. Crkl and Fgf8 Genetically Interact
during Cardiovascular, Pharyngeal, and Skel-
etal Development
(A–D) Pharyngeal arch artery (PAA) formation
assessed by intracardiac ink injections at em-
bryonic day (E) 10.5. Normal PAA formation
and patterning in (A) Fgf8+/2;Crkl+/+and (B)
Fgf8+/+;Crkl2/2 embryos. PAA4 or PAA3–
PAA6 vasculogenesis fails (red arrowheads)
in (C) Fgf8+/2;Crkl+/2 and (D) Fgf8+/2;Crkl2/2
mutants associated with a dilated aortic sac
(AS, [D]). PAAs are numbered.
(E–M) (E, G, I, K, and M) Transverse sections
through the neck and thorax of E15.5 Fgf8+/2;
Crkl+/+ control embryos reveal a (E) normal
left aortic arch, (G) right ventricular OFT, (I)
continuity of aortic and mitral valves, (I and
K) intact atrial and ventricular septae, and
(K) atrioventricular valves. Thymus (thy, [E]),
thyroid (tr, [E]), and parathyroids (arrow-
heads, [M]) are normally located and sized.
(F, H, J, and L) Fgf8+/2;Crkl2/2 mutants dis-
play: ectopic, single-lobed thymi (thy, [F]) or
bilateral thymic aplasia; right aortic arch (ar-
row, [F]) and aberrant subclavian artery (ar-
rowhead, [F]); (H and J) outflow tract defects,
including a Double Outlet Right Ventricle with
a dysplastic common aortic/pulmonary valve
(arrow, [H]) or an aortic valve communicating
with the right ventricle (arrow, [J]); endocar-
dial cushion defects, including a primum
atrial septal defect (red arrow, [L]) and mitral
and tricuspid valve dysplasia (black arrow,
[L]).
(N) Fgf8+/2;Crkl+/2 mutant with unilateral
parathyroid aplasia (arrowhead) and ectopy
(arrow).
(O–Q) Skeleton preparations at E15.5 reveal
markedly short femurs (red double arrows)
in Fgf8;Crkl mutants, even in mutants with
longer crown-rump lengths than (P) controls
(the black, vertical double arrow is the same
length in all specimens).
(R–U) Palate and jaw defects. Sections through the palate reveal complete bony fusion of the palatal shelves (ps) in (R) control versus unfused
shelves causing cleft in (S) mutants (arrow). (U) 30% of Fgf8+/+;Crkl+/2, 50% of Fgf8+/2;Crkl+/2, and 70% of Fgf8+/2; Crkl2/2 mutants have short,
narrow mandibles (arrowhead). Note the severe edema in the Crkl2/2 mutant (arrows, [U]).
fl, forelimbs.The fourth pharyngeal arch artery (PAA4) ultimately
forms the arch of the aorta; disrupted formation or re-
modeling of PAA4 results in interrupted aortic arch or
right aortic arch as well as subclavian artery anomalies
(vascular defects seen in human del22q11 syndrome).
PAA4 formation occurs normally in Fgf8 null heterozy-
gotes (Fgf8+/2), but it is disrupted at lower levels of
Fgf8 that occur in Fgf8 hypomorphic and conditional
mutants, revealing the extreme sensitivity of PAA4 vas-
culogenesis to Fgf8 levels in the developing pharynx
(Abu-Issa et al., 2002; Frank et al., 2002; Macatee
et al., 2003). Although PAA4 forms normally in Crkl2/2
embryos, combined Crkl/Fgf8 deficiency profoundly
disrupts PAA4 formation: 50% of Fgf8+/2;Crkl+/2 and
90% of Fgf8+/2;Crkl2/2 mutants have aplastic or hypo-
plastic fourth PAAs at embryonic day (E) 10.5 (p = 0.05
and p < 0.0001, respectively, relative to Crkl2/2; Figures
1A–1D). Some Fgf8+/2;Crkl+/2 and Fgf8+/2;Crkl2/2 mu-
tants die at mid-gestation and display aortic sac dilata-
tion and no caudal PAAs (12% and 14%, respectively,
Figure 1D); this phenotype was not observed in Crkl2/2
embryos. Recovery from PAA4 formation defects ob-served at E10.5 can occur during remodeling; however,
decreased Fgf8;Crkl dosage frequently prevents recov-
ery, resulting in aortic interruptions and subclavian ar-
tery defects in E15.5 Fgf8+/2;Crkl2/2mutants (Figure 1F;
Table 1).
Ablation of a single copy of Fgf8 in Crkl null homozy-
gotes increases the incidence and severity of intracar-
diac and outflow tract defects (Table 1; Figure 1). Atrio-
ventricular valve dysplasias, which reflect abnormal
formation and/or remodeling of the outflow and endo-
cardial cushions, are more common and markedly
more severe in Fgf8+/2;Crkl2/2 mutants compared to
Crkl2/2 (Figures 1H–1L). Survival of Fgf8+/2;Crkl+/2 and
Fgf8+/2;Crkl2/2 mutants to E15.5 is also compromised
relative to single heterozygotes and Crkl2/2 mutants
(data not shown). Thus, Crkl deficiency reduces the ef-
fective Fgf8 signals required to support early cardiovas-
cular development and embryonic survival.
The pharyngeal pouch endoderm gives rise to the pri-
mordia of the thymus and parathyroids; defects in these
tissues contribute to the morbidity of DiGeorge syn-
drome patients in the form of immunodeficiency and
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73Table 1. Decrements in Fgf8 and Crkl Cause Cardiovascular and Glandular Defects



















+/+; +/+; n = 17 0 0 0 0 0 0 0 1 (6)
+/+; +/2; n = 14 0 0 0 0 0 0 0 1 (7)
+/2; +/+; n = 21 0 0 0 0 0 0 0 2 (10)
+/2; +/2; n = 30 4; 0a (13;0) 0 2a (7) 0 0 2a (7) 9b (30) 18b (60)
+/+; 2/2; n = 16 0; 4b (0;25) 2 (13) 16b (100) 7b; 0 (44) 4b (25) 7b (44) 5 (31) 10, (63)
+/2; 2/2; n = 27 15b; 2 (55;7) 11b (40) 27 (100) 16; 1 (60;4) 13 (48) 19b (70) 18b (67c) 22 (81c)
Percents are in parentheses; totals may exceed 100% due to multiple phenotypes in a single specimen. SCA, retro-esophageal right or isolated
left subclavian artery; HCSCA, high cervical right subclavian artery; VSD, ventricular septal defect; DORV, double outlet right ventricle; TA, per-
sistent Truncus Arteriosus; RAA, circumflex right aortic arch; IAAB, interrupted aortic arch type B; ECC, endocardial cushion defect, mitral,
and/or tricuspid valve dysplasia.
a Incidence of combined cardiovascular defects was statistically different than in the control.
b Statistical significance for the p value was less than 0.05 by using Fisher’s exact test comparing with cell in row above.
c Glandular defects in Crkl2/2 and Fgf8+/2;Crkl2/+ mutants were usually unilateral hypoplasia, while, in Fgf8+/2;Crkl2/2mutants, bilateral defects
and aplastic glands were more common.hypocalcemia, respectively. Fgf8 hypomorphs have fre-
quent aplasia of these glands and associated T cell de-
ficiency (Frank et al., 2002). The size and location of the
thymus and parathyroids are normal in Fgf8 or Crkl het-
erozygotes; however, Fgf8+/2;Crkl+/2 mutants have the
same incidence of glandular ectopy asCrkl2/2 embryos.
Moreover, glandular phenotypes are exacerbated in
Fgf8+/2;Crkl2/2 mutants (Figure 1F; Table 1), indicating
a dosage-sensitive interaction between Fgf8 and Crkl
during pharyngeal pouch development.
Humans with del22q11 have variable appendicular
and craniofacial skeletal malformations and short stat-
ure (Bird and Scambler, 2000; Emanuel et al., 2001;
Motzkin et al., 1993). Patterning, outgrowth, and the ul-
timate length of limb bony elements are all sensitive to
Fgf8 signaling from epithelial cells to underlying mesen-
chyme (Boulet et al., 2004; Lewandoski et al., 2000;
Moon and Capecchi, 2000). Femurs of Fgf8+/2;Crkl+/2
and Fgf8+/2;Crkl2/2 mutants are an average of 35%
shorter than Fgf8+/2 and Crkl2/2 littermates (Figures
1O–1Q). Cleft palate and mandibular hypoplasia are fre-
quently observed in patients with del22q11 syndrome,
and in Fgf8 hypomorphic or conditional mutant mice
(Abu-Issa et al., 2002; Frank et al., 2002; Macatee
et al., 2003; Trumpp et al., 1999). A synergistic interac-
tion between Fgf8 and Crkl during formation of the
bony palate is manifest by a dramatic increase in the in-
cidence of cleft palate from 5% in Fgf8+/2;Crkl+/2 or
Crkl2/2mutants to 55% in Fgf8+/2;Crkl2/2mutants (Fig-
ures 1O–1S). Mandibular hypoplasia is apparent in 50%
of Fgf8+/2;Crkl+/2, 60% of Crkl2/2, and 85% of Fgf8+/2;
Crkl2/2 mutants (Figure 1U).
Loss of Crkl Decreases Survival of Neural Crest
and the Contribution of Neural Crest to the
Outflow Tract and Pharyngeal Arches
Neural crest cells (NC) migrate from the dorsal neural
tube and make crucial contributions of mesenchyme
to the pharyngeal arches, OFT septum, and pharyngeal
glands (Jiang et al., 2000). The OFT myocardium is com-
posed of cells derived from the Fgf8-dependent anterior
heart field in splanchnic mesoderm (SM) (Kelly and
Buckingham, 2002; E. Park and A.M.M., submitted). Ab-normal apoptosis of NC and SM in Fgf8 hypomorphs
and domain-specific conditional mutants is associated
with craniofacial, vascular, and OFT defects (Abu-Issa
et al., 2002; Frank et al., 2002; Macatee et al., 2003;
E. Park and A.M.M., submitted). We found a marked
excess of apoptotic cells in the pharynx of Crkl2/2,
Fgf8+/2;Crkl+/2, and Fgf8+/2;Crkl2/2 mutants, including
cells streaming into the pharynx from the neural tube
(Figures 2A–2E). Since Crkl is expressed in NC adjacent
to Fgf8-expressing domains, we immunohistochemi-
cally labeled NC with the marker AP-2a and assayed
for apoptosis. This revealed multiple regions of apopto-
tic NC en route to the pharyngeal arches in Crkl2/2,
Fgf8+/2;Crkl+/2, and Fgf8+/2;Crkl2/2 mutants (Figures
2F–2J). Sections revealed that excess apoptosis oc-
curred in the pharyngeal epithelia and SM, in addition
to the NC (Figures 2K–2M0). Levels of apoptosis mirror
decreases in Fgf8 and/or Crkl gene dosage.
To evaluate NC populations inCrkl2/2 embryos, we la-
beled this cell lineage by using the Rosa26-Cre reporter
and theWnt1Cre transgene (Jiang et al., 2000). AllCrkl+/+
and Crkl+/2 embryos had dense populations of lacZ-
positive cells throughout the PAs and OFT (Figure 2N, ar-
rows; data not shown), whereas contribution of NC to
these structures was obviously decreased in Crkl2/2
mutants (Figure 2O, arrows).
These phenotypes demonstrate that Fgf8 andCrkl ge-
netically interact to regulate the development of struc-
tures affected in patients with del22q11 syndrome and
suggest that Crkl is required for normal responses to
Fgf8 in multiple morphogenetic pathways during em-
bryogenesis. To investigate whether this interaction re-
flects the function of Crkl downstream of FgfRs (versus
functions in parallel molecular pathways that influence
development of these structures), we examined the ef-
fects of Crkl deficiency on expression of Fgf8 target
genes, activation of MAP kinases, and intracellular bio-
chemical signal transduction in vivo.
Crkl Regulates Expression of Fgf8 Target Genes
Fgf8 signaling stimulates transcription of the ETS do-
main DNA binding proteins Erm and Pea3 (Firnberg
and Neubuser, 2002; Raible and Brand, 2001; Roehl
Developmental Cell
74Figure 2. Decreased Neural Crest Population
of the Outflow Tract and Caudal Pharyngeal
Arches ofCrkl2/2 Embryos Is Associated with
Abnormal Apoptosis
Genotypes are listed above the columns, and
assay type is listed at the left; pharyngeal
arches are numbered.
(A–E) Whole-mount E10.5 allelelic series as-
sayed for apoptosis with antiactivated cas-
pase3. Right, lateral views at 803. The yellow
arrowheads indicate domains of abnormal
apoptosis in Fgf8;Crkl and Crkl2/2 mutants,
including streams of neural crest (NC) origi-
nating in the hindbrain.
(F–J) Whole-mount preparations of E9.5 alle-
lic series assayed for the NC/ectoderm
marker AP2a (green) and antiactivated cas-
pase3 (red); right, lateral views at 3203. Yel-
low colabeled cells are apoptotic NC and
ectoderm.
(K–M) E9.5 transverse cryosections through
the second pharyngeal arch assayed for
AP2a (green) and apoptosis (TUNEL, red); nu-
clei are stained blue with Hoechst. Note the
multiple cell types undergoing aberrant apo-
ptosis including: NC (double-labeled, yellow),
pharyngealectoderm,endoderm,andsplanch-
nic mesoderm. nt, neural tube.
(K0–M0) As above, sections through the third
pharyngeal arch. fg, foregut.
(N and O) Wnt1Cre and Rosa26-Cre reporter
(R26R) strains were used to label NC deriva-
tives in E10.5 Crkl2/2 and wild-type embryos.
Cells stained red outside the neural tube are
NC derivatives. The outflow tract of the (O)
mutant is minimally stained compared to (N)
wild-type. NC cells extend from dorsal to ven-
tral in the PAs of wild-type embryos, but these
extensions are not continuous or as extensive
in the caudal PAs of the Crkl2/2 mutants (ar-
rowheads). Arrows indicate the OFT/aortic
sac.and Nusslein-Volhard, 2001). Fgf/FgfR interactions trig-
ger phosphorylation of Erm protein via activated MAPK/
ERKs, causing it to bind its transcriptional targets (Jan-
knecht et al., 1996; O’Hagan et al., 1996; Tsang and Da-
wid, 2004). Whole-mount in situ hybridization revealed
decreased Erm and Pea3 expression in the pharyngeal
arches of Crkl2/2 mutants, consistent with a role for
Crkl in mediating Fgf signals (Figures 3A–3J). Decre-
ments in Erm and Pea3 expression in the pharyngeal
arches mirrored those in Fgf8 and Crkl gene dosage,
and, in Fgf8+/2;Crkl2/2 mutants, Erm expression was
less than that detected in Fgf8 hypomorphs (data not
shown). Altered expression of the Fgf8 target gene
Barx1 was noted in the hypoplastic caudal arches of
Fgf8+/2;Crkl2/2 mutants (Figures 3K–3O). Decreased
Erm andPea3 expression correlated with levels of phos-
phorylated Erk1/2 in the pharyngeal arches and limb
buds of Crkl2/2 and Fgf8;Crkl compound mutant em-
bryos. In Crkl heterozygote controls (Figure 3Q), high
levels of phosphorylated Erk are detected in the pharyn-
geal epithelium and mesenchyme. In compound mu-
tants and Fgf8 hypomorphs (Figures 3R–3T, and data
not shown), this pattern of Erk phosphorylation waslost. Thus, expression of known Fgf8 target genes and
activation of MAP kinases in Fgf8-responsive tissues
depend on Crkl function in vivo.
Crkl Binds Activated Fgf Receptors 1 and 2
and Is Required for Downstream Cellular
Responses to Fgf8
We investigated whether Crkl interacts with FgfRs to
mediate Fgf8 signaling. In primary cultures of mouse
embryonic fibroblasts (MEFs), FgfR1 and FgfR2 are
rapidly tyrosine phosphorylated in response to Fgf8b
stimulation (Figures 4A and 4B). These activated recep-
tors bind directly to the SH2 domain of Crkl in vitro
(Figure 4C). Furthermore, Crkl forms stable complexes
with endogenous FgfR1 and FgfR2 proteins in normal
Fgf8b-stimulated MEFs in vivo, indicating that formation
of these complexes is a physiologic event (Figure 4D).
While association of Crkl with these receptors was read-
ily detectable, only a minute amount of Crk was coimmu-
noprecipitated with the FgfRs compared to the level of
Crk in the cell. Thus, Crkl interacts with activated FgfRs
far more efficiently than Crk. It is noteworthy that, in con-
trast to results obtained with overexpressed or chimeric
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of Fgf8 Target Genes and Alters MAPK Acti-
vation In Vivo
Genotypes are listed above the columns;
all views are tight. Lateral and pharyngeal
arches are numbered.
(A–E) Right, lateral views of pharyngeal
arches of E10.5 embryos after whole-mount
in situ hybridization with an Erm antisense ri-
boprobe. Note the decreasing levels of ex-
pression in the pharyngeal arches (red arrow-
heads) of (C) Fgf8+/2;Crkl+/2, (D) Crkl2/2, and
(E) Fgf8+/2;Crkl2/2 mutants relative to (A and
B) controls. Expression in the lung bud (black
arrowheads) is intact.
(F–J) As above, after whole-mount in situ hy-
bridization with a Pea3 antisense riboprobe.
(K–O) As above, after whole-mount in situ hy-
bridization with a Barx1 antisense riboprobe.
(P–T) Anti-phospho-Erk1/2 staining of E10.5
embryos. Optical confocal sections were ob-
tained at 2 mm intervals; representative, ana-
tomically matched section images are shown
through the casudal PAs. The levels of these
activated MAP kinases are decreased (red ar-
rowheads) in the pharyngeal epithelia and
mesenchyme in response to decreased Crkl
and/or Fgf8 gene dosage. HT, heart.FgfRs in transformed cell lines (Chellaiah et al., 1999;
Larsson et al., 1999; Ornitz et al., 1996), in this primary
embryonic culture model, Fgf8 activates FgfR1 in addi-
tion to FgfR2.
We further interrogated the role of Crkl in mediating
functional responses to Fgf8 in MEFs. Wild-type MEFs
migrate robustly toward a source of Fgf8b in a modified
Boyden chamber assay, whereas MEFs isolated from
Crkl2/2 embryos do not (p = 0.0001, Figure 5A). Chemo-
taxis to Fgf8 can be rescued by expression of Crkl from
a plasmid transfected into the mutant cells prior to assay
(Figure 5A, Crkl2/2+CRKL). The fact that Crkl2/2 MEFs
migrate normally toward serum, epidermal growth fac-
tor (EGF), or platelet-derived growth factor (PDGF) (Fig-
ures 5A and 5B) demonstrates that the requisite machin-
ery for cell motility is intact, and that migratory defects
observed in Crkl2/2 cells reside in Crkl-dependent path-
ways specific to Fgf8 signal transduction.
The cellular response to Fgfs occurs after Fgf ligand
binds to the high-affinity cell surface FgfRs, triggering
receptor dimerization, autophosphorylation, and subse-
quent activation of the Ras/Raf/Mek pathway upstream
of Erk1/2 MAP kinases (Hadari et al., 2001; Reuss and
von Bohlen und Halbach, 2003). We found that Fgf8b in-
duces robust and sustained activation of Erk1/2 MAP
kinases in wild-type MEFs (Figure 5C). In contrast, in
Crkl2/2 MEFs, Fgf8b induces only minor activation of
Erk1/2. Furthermore, the effective minimal concentra-
tion of Fgf8b required to induce detectable activation
of Erk1/2 is approximately 10-fold greater in Crkl2/2
cells (20 ng/ml) than in wild-type cells (2.0 ng/ml,
Figure 5D).Since FgfRs are RTKs, we examined the profile of
tyrosine-phosphorylated proteins in MEFs after Fgf8b
stimulation, with particular attention paid to the docking
protein Frs2. In response to Fgf stimulation, Frs2 links
FgfR activation to the Ras/MAPK signaling pathway by
targeting signaling molecules to the plasma membrane.
For example, activated Frs2 recruits the adaptor protein
Grb-2/Sos, which sequentially recruits Ras to the FgfR
complex (Hadari et al., 1998, 2001; Kouhara et al.,
1997; Larsson et al., 1999). While the overall content of
protein tyrosine phosphorylation is comparable in
Crkl2/2 and wild-type MEFs, some species are relatively
hypophosphorylated inCrkl2/2 cells after Fgf8b stimula-
tion (Figure 5E). One species has a molecular weight of
approximately 90 kDa and comigrates with tyrosine-
phosphorylated species of Frs2 when the same blot is
probed with anti-Frs2 antibody (Figure 5F). Immunopre-
cipitation confirms that Fgf8b-induced tyrosine phos-
phorylation of Frs2 depends partially on the presence
of Crkl (Figure 5G). Furthermore, the level of Frs2 tyro-
sine phosphorylation can be titrated in Crkl2/2 cells
by varying the level of Crkl produced from a transgene
(Figure 5H). These findings strongly support the role of
Crkl in transducing intracellular biochemical responses
to Fgf8 during morphogenesis.
Discussion
We have demonstrated that Fgf8 andCrkl genetically in-
teract in expression domains that regulate the formation
of organs and structures affected in human patients with
del22q11 syndrome. Furthermore, we have shown that
Developmental Cell
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an interaction with FgfRs 1 and 2, providing another
mechanism for generating dosage-sensitive, context-
dependent cellular responses to Fgf signaling by down-
stream intracellular signal modulation (Dailey et al.,
2005; Echevarria et al., 2005; Sivak et al., 2005; Tsang
and Dawid, 2004). Fgf8 also signals in Crkl-independent
pathway(s) because the phenotypes of Fgf82/2 mutants
Figure 4. Fgf Receptors 1 and 2 Are Activated, and Interact with
Crkl, in Response to Fgf8
(A and B) Fgf8 stimulates tyrosine phosphorylation of FgfR1 and
FgfR2. Anti-receptor antibodies were used to immunoprecipitate
Fgf8b-treated MEF lysates (IP), and the products were separated
by electrophoresis. Immunoblotting (WB) with anti-phosphotyrosine
antibody (pY) reveals that phosphorylation of both receptors occurs
in response to 10 ng/ml Fgf8b.
(C) Activated FgfRs interact with Crkl via its SH2 domain. MEFs were
treated with 10 ng/ml Fgf8b, and proteins from lysates that bind to
the SH2 domain of Crkl were pulled down with GST-Crkl SH2 cou-
pled to glutathione-Sepharose beads. Total MEF lysates (total ly-
sate) or proteins pulled down (CRKL SH2 pull-down) were blotted
and probed with anti-FgfR1 or anti-FgfR2 antibodies (WB).
(D) Endogenous FgfRs associate with Crkl, preferentially with Crk.
Proteins that interact with endogenous FgfR1 or FgfR2 were precip-
itated from control, and Fgf8b-treated MEF lysates were precipi-
tated with anti-FgfR antibody-coupled protein A agarose beads
(IP). Immunoprecipitates were separated by electrophoresis and
probed with anti-Crkl or -Crk antibody (WB). The relative level of
Crkl or Crk in 10 mg total lysate was determined in parallel compared
to that associated with FgfR (total lysate).occur earlier and are more profound than Crkl2/2 homo-
zygotes (Meyers et al., 1998).
Disruption of either Tbx1 or Crkl, the mouse orthologs
of two 22q11 genes, generates features of del22q11
syndrome in mice, as does Fgf8 deficiency (Abu-Issa
et al., 2002; Frank et al., 2002; Guris et al., 2001; Jerome
and Papaioannou, 2001; Lindsay et al., 2001; Merscher
et al., 2001). It has become clear that TBX1 dysfunction
plays an important role in human del22q11 syndrome
(Yagi et al., 2003). However, phenotypic variability in hu-
mans and mice with 22q11-like deletions or single gene
mutations supports the existence of modifier genes at
22q11 and elsewhere (Frank et al., 2002; Hu et al.,
2004; Lindsay, 2001; Lindsay and Baldini, 2001; Schinke
and Izumo, 2001; Vitelli et al., 2002a, 2002b; Yagi et al.,
2003). The accompanying paper by Guris and col-
leagues (Guris et al., 2006 [this issue of Developmental
Cell]) demonstrates a genetic interaction between Tbx1
and Crkl and confirms that del22q11 is a contiguous
gene syndrome.
Mounting evidence indicates that Fgf8 operates in
critical developmental and molecular pathways with
both Crkl and Tbx1 during cardiovascular and pharyn-
geal development (Figure 6). Fgf8 and Tbx1 are both ex-
pressed in the pharyngeal epithelia and mesoderm. The
relationship between Tbx1 transcriptional activity and
Fgf8 expression appears to be cell-type specific: Fgf8
expression is present in the ectoderm, but is absent in
the endoderm of Tbx1 null mutants, and a Tbx1-respon-
sive enhancer regulates expression of an Fgf8 transgene
in OFT mesoderm (Hu et al., 2004). Fgf8 genetically inter-
acts with Tbx1 to increase penetrance of aortic arch de-
fects in Tbx1 null heterozygotes (Vitelli et al., 2002b),
possibly through mutual effects on Gbx2 (Byrd and
Meyers, 2005).
Like Crkl, FgfRs 1 and 2 are ubiquitously expressed in
pharyngeal tissues, including neural crest, at E8.5–10.5
(Bachler and Neubuser, 2001; Blak et al., 2005; Orr-
Urtreger et al., 1991; Peters et al., 1992; Yamaguchi
et al., 1992; Guris et al., 2001; A.M.M., unpublished
data). The different sensitivity of heart, vasculature, cra-
niofacial, and limb morphogenesis to altered Crkl and
Fgf8 dosage suggests that Crkl functions downstream
of multiple Fgf/FgfRs in different morphogenetic path-
ways and that reliance of a particular Fgf/FgfR signaling
event on Crkl-mediated signal transduction is context
dependent. We have previously shown that the pharyn-
geal ectoderm is the source of Fgf8 required for PAA4
formation/remodeling (Macatee et al., 2003). Disrupted
PAA4 vasculogenesis in Fgf8;Crkl mutants suggests
an early role for Crkl in mediating Fgf signals from the ec-
toderm. Notably, failed vasculogenesis of PAAs3–6 re-
sulting in mid-gestational lethality of the most severely
affected Fgf8;Crkl mutants also occurs after ablation
of both Fgf8 and Fgf4 from the pharyngeal ectoderm
(L. Francis and A.M.M., unpublished data). OFT septa-
tion and alignment are independently regulated by
Fgf8 emanating from pharyngeal endoderm and anterior
heart field mesoderm, respectively (E. Park and A.M.M.,
submitted). Thus, the presence of alignment and septa-
tion defects in Fgf8+/2;Crkl2/2 mutants indicates that
Crkl also plays a role in transduction of Fgf8 from these
expression domains. Although Fgf10 and Fgf4 are not
independently required in cardiovascular or craniofacial
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77Figure 5. Crkl Is Required for Fgf8-Induced
Chemotaxis and Activation of Downstream
Biochemical Signaling Mediators
WB, western blot; IP, immunoprecipitation.
(A and B) Modified Boyden chamber assay of
Crkl2/2 MEFs migrating toward Fgf8b ([A], 10
ng/ml), fetal bovine serum ([A], 5%), PDGF
([B], 50 ng/ml), or EGF ([B], 20 ng/ml) com-
pared to wild-type MEFs, orCrkl2/2MEFs ex-
pressing CRKL as a transgene at a level com-
parable to wild-type cells. Control groups
(CTR) had buffer with no growth factor or se-
rum in the chambers. Error bars indicate
standard deviation of sample data (n = 4).
(C and D) Maximal MAPK activation in re-
sponse to Fgf8b is Crkl dependent. (C) Cell ly-
sates were prepared after incubation with 25
ng/ml Fgf8b and phosphorylated Erk1 and
Erk2 were detected by Western blot. Average
phospho-Erk levels (n = 2) are graphically
represented as fold activation relative to
that at 0 min in wild-type cells. Reblotting
with anti-Erk antibody indicated equal levels
of total Erk1/2 proteins (not shown). (D)
MEFs exposed to varying concentrations of
Fgf8b were tested for activation of Erk1
(p44) and Erk2 (p42). Cell lysates were pre-
pared after 10 min of incubation with Fgf8b
at the concentrations listed. The average
phospho-Erk levels (Erk1 + Erk2) in two ex-
periments are graphically represented below
as fold activation relative to unstimulated lev-
els. The levels of phospho-Erk were normal-
ized relative to the corresponding total Erk
levels (Erk1 + Erk2).
(E–H) (E) Crkl regulates the level of Fgf recep-
tor substrate 2 (Frs2) phosphorylation in re-
sponse to Fgf8b. Anti-phosphotyrosine (pY)
blot of total cell lysates prepared at the time
indicated after incubation with 25 ng/ml
Fgf8b. Black arrowheads indicate a 90 kDa
protein phosphorylated in response to Fgf8b;
note the decreased intensity of this band in
Crkl2/2 MEFs at all time points. (F) Anti-Frs2
antibody reprobe of blot shown in (E); the
black line denotes Fgf8-stimulated phos-
phorylation of Frs2 (corresponds to the black
arrowhead on the pY blot), This species of
Frs2 is relatively hypophosphorylated in Crkl2/2 MEFs. (G) Anti-phosphotyrosine blot of Frs2 immunoprecipitated from Fgf8b-stimulated
MEFs. ‘‘+Crkl’’ samples are two different Crkl2/2 cell lines infected with Crkl-producing retrovirus (see [H]); Fgf8b-stimulated phosphorylation
of Frs2 occurs at 1.33 and 1.03 wild-type levels in these cell lines, while that in Crkl2/2 MEFs is only 0.53. (H) Quantitation of Crkl levels: the
+Crkl cell line 1 produces Crkl at 23 compared to wild-type levels, and the +Crkl cell line 2 produces Crkl protein at 1.23 compared to wild-
type levels.development (Min et al., 1998; Moon et al., 2000; Sekine
et al., 1999; Sun et al., 2000; L. Francis and A.M.M., un-
published data), they are also expressed in the develop-
ing heart and pharynx; we are investigating their func-
tional redundancy with Fgf8 and their reliance on Crkl
during cardiovascular development.
In vitro mitogenic assays suggest that Fgf ligand/re-
ceptor preferences exist (Ornitz and Itoh, 2001; Ornitz
et al., 1996), but it has been unclear how preferences ex-
hibited by transformed cells in culture apply to the highly
plastic, tissue-specific environments present in devel-
oping embryos. Our data indicate that Fgf8b activates
both FgfR1 and FgfR2, and that these receptors interact
with Crkl in response to Fgf8 stimulation. Moreover, Crkl
is required for MAPK activation and high-level phos-
phorylation of FRS2 in response to Fgf8b in murine em-bryonic fibroblasts. These findings are consistent with
accumulating evidence suggesting that FgfR1 and
FgfR2 mediate many responses to Fgf8 (Arman et al.,
1998; Celli et al., 1998; Deng et al., 1994, 1997; Rossant
et al., 1997; Sun et al., 1999; Trokovic et al., 2003; Xu
et al., 1998). We recently discovered that FgfR1 is re-
quired in the pharyngeal epithelia to support formation
of the PAAs (L. Francis and A.M.M., unpublished data).
Crkl functions in multiple signaling pathways, and,
thus, Crkl2/2 mutant phenotypes likely represent the ef-
fects of altered transduction and integration of FGF and
VEGF, EGF, PDGF, and BMP/TGFb signaling, in addition
to perturbed focal adhesion assembly and function
(Feller, 2001; Feller et al., 1998; Li et al., 2002, 2003;
Presta et al., 2005). For example, TGFb2 null mice have
DORV, VSD, and dysplastic atrioventricular and outflow
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78Figure 6. A Model for Interaction between
Crkl-Modulated Fgf Signaling and Tbx1 Func-
tion in the Developing Pharyngeal Arches
Secreted Fgf8 signals to target cells via para-
crine (1) or autocrine (2) pathways. Ligand-
stimulated FgfR activation triggers receptor
autophosphorylation and interaction with sig-
naling mediators, including Crkl. Erk-depen-
dent and -independent pathways affect gene
expression, cell survival, and other functions.
Phosphorylated MAPK/ERKs downstream of
Crkl activate existing ETS proteins (e.g., Erm)
and also stimulate their transcription. Tbx1
is expressed in FgfR-expressing pharyngeal
mesoderm, ectoderm, and endoderm; in these
cells, Tbx1 and Fgf signaling may regulate ex-
pression of common transcriptional targets
such as Gbx2. Furthermore, both Fgf8 and
Tbx1 have been shown to have non-cell au-
tonomous effects on neural crest survival and
function.valves (Sanford et al., 1997), phenotypes also present in
Crkl2/2 and Fgf8;Crkl mutants. As in gastrulation and
neurulation (Pera et al., 2003), it is likely that Smad-
dependent and -independent inputs downstream of
TGFb receptors converge on the Ras/Erk/MAPK and
PI3K/Akt pathways, which are also downstream of
FgfRs (Derynck and Zhang, 2003; Zhang and Derynck,
1999). Reduced Fgf8 dosage in Fgf8;Crkl compound
mutants impinges further upon Fgf-sensitive pathways
impaired by Crkl deficiency, thus providing a biochemi-
cal basis for the genetic interactions observed in vivo.
These results strongly support the hypothesis that dis-
rupted FGF8 signaling contributes to the pathogenesis
of congenital cardiovascular disease, and that FGF8
function may modify phenotypes in humans with 22q11
mutations involving TBX1 or CRKL.
Experimental Procedures
Mice
TheCrkl null (Crkl2), Fgf8 hypomorphic (Fgf8H), and Fgf8 null (Fgf82)
alleles were described previously (Frank et al., 2002; Guris et al.,
2001; Moon and Capecchi, 2000). These alleles were originally tar-
geted in 129Sv-derived ES cells and then backcrossed 3–4 genera-
tions into C57BL/6J prior to interstrain crosses.
In Situ Detection of Apoptosis
Primary and secondary antibodies and the methods employed to
detect AP2a in neural crest, TUNEL, and Hoechst staining of nuclei
in whole-mount and on cryosectioned specimens were previously
described (Macatee et al., 2003). In whole-mount specimens, apo-
ptotic cells were detected with anti-cleaved caspase 3 (Cell Signal-
ing Technology, 9664S).
Marking the Neural Crest
Neural crest cells were genetically labeled by using the R26R and
Wnt1Cre strains (kind gifts from P. Soriano and A.P. McMahon, re-
spectively). These strains were maintained by continual backcross
with C57BL/6J for more than 11 generations. Embryos were stained
with Salmon-gal (Biosynth) by standard protocols.Whole-Mount In Situ Hybridization
Whole-mount in situ RNA hybridization was performed by using
a standard protocol (Guris et al., 2001). Experiments were repeated
a minimum of three times.
Whole-Mount Detection of MAP Kinase Activation
Phosphorylated Erk1 and Erk2 were detected as described (Corson
et al., 2003), but with minor modifications: rabbit polyclonal anti-
phosphorylated p44/p42 was used (Cell Signaling Technology,
9101S). After dissection in cold PBS, the embryos were fixed over-
night at 4ºC, washed in 13 PBS and 0.5% NP40, then dehydrated/
rehydrated through a methanol series. Embryos were blocked with
13 PBS/5% goat serum/0.1% Triton X-100 and were incubated
overnight at 4ºC with primary antibody diluted 1:350 in PBST.
Washes were followed by repeated blocking and incubation over-
night with secondary antibody (Alexa 594 goat anti-rabbit; diluted
1:200 in PBST). Fluorescence of 2 mm optical sections under
a 103 objective were recorded with an Olympus 1X70 Fluoview con-
focal microscope.
Cellular and Biochemical Analysis
Preparation of mouse embryonic fibroblasts and assay of cell motil-
ity with a modified Boyden chamber were described previously
(Li et al., 2003). Western blots and immunoprecipitation were per-
formed by using standard procedures. GST-CRKL SH2 generated
in E. coliwas isolated by glutathione-Sepharose beads (GE Biotech-
nology) prior to pull-down assays.
Rabbit anti-CRKL (C-20), anti-CRK-II (C-18), anti-FGFR1 (C-15),
anti-FGFR2 (C-17), and anti-FRS2 (H-91) antibodies were purchased
from Santa Cruz Biotechnology. In some experiments, mouse
monoclonal anti-CRKL (Upstate Biotechnology), anti-CRK (BD Phar-
mingen), and anti-FGFR1 (Zymed) were used for compatible combi-
nations of antibody host species for immunoprecipitation, followed
by immunoblot analysis, and for confirmation. Mouse monoclonal
anti-phosphotyrosine (PY99) antibody was obtained from Santa
Cruz Biotechnology. Anti-phospho Erk p44/42 (pTEpY) monoclonal
(E10) and anti-p44/42 polyclonal antibodies were obtained from
Cell Signaling Technology.
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